Parameter
| Biomarker | PIK3CA | Full name | Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | Molecular Type | Nucleic acid (DNA) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | 110 kDa | Core Functional Dimensions | Prognosis and therapeutic targets | |
| Disease | Angiosarcoma | Disease Subtypes | / | ||
| Organ | All cells (PI3K pathway) | Test Sample / Technology Platform | Organization (NGS, WES, custom TaqMan detection) | ||
| Pathobiological Mechanisms | Activating mutations lead to abnormal activation of the PI3K/Akt/mTOR pathway and promote cell survival and proliferation | ||||
| Clinical Availability Status | Validation: breast subtypes enrichment | ||||
| Notes and Dynamics | Mutation frequency of 13% (0% 45%), is associated with poor prognosis, Alpelisib PI3K inhibitors in clinical trials | ||||